Publication: Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor
7
item.page.dc.date.issued
1998-01-01
item.page.dc.type
item.page.dc.identifier.issn
09594973
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-0031656655
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Anti-Cancer Drugs. Vol.9, No.7 (1998), 621-623
punsarn.item.page.citation
Andrzej P. Kudelka, Apichai Vasuratna, Creigton L. Edwards, Kristan Augustine, Mongkol Benjapibal, Claire F. Verschraegen, John J. Kavanagh Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor. Anti-Cancer Drugs. Vol.9, No.7 (1998), 621-623. doi:10.1097/00001813-199808000-00007 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18330
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
A 19-year-old woman with refractory juvenile granulosa cell tumors had persistent disease after PVB (cisplatin, vinblastino and bleomycin) and multiple high doses of ICE (ifosfamide, carboplatin and etoposide) with peripheral stem cell support. She achieved stable disease for 4 months with low dose intensity gemcitabine of 500 mg/m2/week. The planned dose had been 1250 mg/m2/week. The dose intensity was limited by myelosuppression especially thrombocytopenia. The use of thrombopoietic, in addition to erythropoietic and myelopoletic, agents may permit higher dose intensity of gemcitabine after bone marrow ablative therapy with resulting greater anti tumor activity.